Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERENADE open-label extension study of macitentan in HFpEF with pulmonary vascular disease
MOH_2019-03-17_006027Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of macitentan in heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease (PVD), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Not specified. Started Jan 2019; status: completed.
02
Drugs
macitentan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)pulmonary vascular disease (PVD)
Beyond the preview
Go deeper on MOH_2019-03-17_006027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-17_006027.